Venture
Technologies
Pharmaceutical Drug
Therapeutic
Indication
Fibrosis
Oncology
Additional Information
Women Founded
Synthis is developing a novel immuno-oncology (IO) therapeutic that reserves immune suppression in metastatic melanoma patients who have failed immune checkpoint blockade.
Team:
Dori T. Karyat, Ph.D., Founder